Sagimet Biosciences Inc. (SGMT) Investor Relations Documents

Sagimet Biosciences Inc. (SGMT) investor relations documents from the company's IR site: 2 presentations, 22 press releases; latest deck 2026-08-13. Read in-app with summaries. First-party data.

Sagimet Biosciences Corporate Presentation: Sagimet is developing FASN inhibitors for acne and metabolic diseases, with a US Phase 3 trial for denifanstat in moderate to severe acne starting in 2H 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-17Press releaseSagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-13PresentationSagimet Biosciences Corporate Presentation
2026-08-13Press releaseSagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent an
2026-08-11Press releaseSagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-04Press releaseSagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-06-29Press releaseSagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
2026-06-22Press releaseSagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Ru
2026-05-27Press releaseSagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
2026-05-13Press releaseSagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
2026-05-12Press releaseSagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-11Press releaseSagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermato
2026-04-27Press releaseSagimet Biosciences Provides Strategic and Corporate Updates
2026-04-27Press releaseSagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
2026-04-20Press releaseSagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
2026-04-06Press releaseSagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Cros
2026-04-02PresentationView Presentation
2026-03-11Press releaseSagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
2026-02-25Press releaseSagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
2026-02-05Press releaseSagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
2026-02-02Press releaseSagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the
2026-01-08Press releaseSagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Press releaseSagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Press releaseSagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Press releaseSagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

SGMT overview · SGMT earnings · SGMT financials · SGMT KPIs · SGMT ownership · SGMT peers · SGMT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.